Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HMOX1 | P09601 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.41 |
| ▸ | SOD1 | P00441 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9996057 | 0.99 | CYP19A1 (0.49) | CYP19A1POLBHMOX1TSHRMAPK1 | |
| SCHEMBL11356373 | 0.95 | CYP19A1 (0.48) | CYP19A1POLBHMOX1CYP11B1CYP11B2 | |
| Hydrochloric Acid SCHEMBL11356376 | 0.94 | CYP19A1 (0.47) | CYP19A1POLBHMOX1CYP11B1CYP11B2 | |
| SCHEMBL11248520 | 0.88 | CYP19A1 (0.48) | CYP19A1POLBCYP11B1CYP11B2SOD1 | |
| SCHEMBL11188956 | 0.88 | POLB (0.41) | CYP19A1POLBHMOX1CYP11B1CYP11B2 | |
| Hydrochloric Acid SCHEMBL11353678 | 0.87 | CYP19A1 (0.45) | CYP19A1POLBHMOX1CYP11B1CYP11B2 | |
| SCHEMBL11032970 | 0.85 | HMOX1 (0.44) | CYP19A1HMOX1 | |
| Hydrochloric Acid SCHEMBL11355501 | 0.85 | CYP19A1 (0.41) | CYP19A1POLBHMOX1 | |
| SCHEMBL10247576 | 0.84 | TSHR (0.50) | CYP19A1POLBHMOX1TSHRMAPK1 | |
| SCHEMBL11247856 | 0.83 | CYP19A1 (0.46) | CYP19A1POLBCYP11B1CYP11B2SOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0001926-B1 | 1-(NAPHTHYLETHYL)IMIDAZOLE DERIVATIVES, THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SYNTEX (U.S.A.) INC. (US) | 1981-04-29 | — | — | EP | claimed |
| EP-0001926-A1 | 1-(Naphthylethyl)imidazole derivatives, their preparation, and pharmaceutical compositions containing them | SYNTEX (U.S.A.) INC. (US) | 1979-05-16 | — | — | EP | claimed |
| US-4150153-A | ANTICONVULSANTS, GASTRIC ANTISECRETORY AGENTS | SYNTEX (U.S.A.) INC. (US) | 1979-04-17 | — | — | US | claimed |
| US-20140155445-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2014-06-05 | — | — | US | disclosed |
| US-20140155445-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2014-06-05 | — | — | US | disclosed |
| US-20110319459-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | OSTA BIOTECHNOLOGIES (CA) | 2011-12-29 | — | — | US | disclosed |
| US-20110319459-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | OSTA BIOTECHNOLOGIES (CA) | 2011-12-29 | — | — | US | disclosed |
| EP-0001926-B1 | 1-(NAPHTHYLETHYL)IMIDAZOLE DERIVATIVES, THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SYNTEX (U.S.A.) INC. (US) | 1981-04-29 | — | — | EP | disclosed |
| EP-0001926-A1 | 1-(Naphthylethyl)imidazole derivatives, their preparation, and pharmaceutical compositions containing them | SYNTEX (U.S.A.) INC. (US) | 1979-05-16 | — | — | EP | disclosed |
| US-4150153-A | ANTICONVULSANTS, GASTRIC ANTISECRETORY AGENTS | SYNTEX (U.S.A.) INC. (US) | 1979-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319459-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | TXNRD2, HMOX1, HMOX2 | CYP19A1 884/4885POLB 823/4885HMOX1 2/4885 |
| US-20140155445-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | HMOX1, HMOX2, CYC1 | CYP19A1 641/4885POLB 643/4885HMOX1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.